Implication of bisphosphonate use in the treatment of SAPHO syndrome: Case report and discussion of current literature

Gorecki, Patricia; Stockmann, Philipp; Distler, Jörg H.w.; Wuest, Wolfgang; Schmidt, Daniela; Neukam, Friedrich Wilhelm; Nkenke, Emeka; Wehrhan, Falk

DOI: 10.1016/j.jmhi.2015.04.002

License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
https://doi.org/10.1016/j.jmhi.2015.04.002

Link to publication on Research at Birmingham portal

Publisher Rights Statement:
Published under a Creative Commons Non-Commercial No Derivatives license: http://creativecommons.org/licenses/by-nc-nd/4.0/.

Eligibility for repository checked June 2015

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?).
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
REGULAR ARTICLES

Implication of bisphosphonate use in the treatment of SAPHO syndrome: Case report and discussion of current literature

Patricia Gorecki a,* , Philipp Stockmann b, Jörg H.W. Distler c, Wolfgang Wuest d, Daniela Schmidt e, Friedrich Wilhelm Neukam f, Emeka Nkenke b,g, Falk Wehrhan b

a Department of Oral Surgery, The School of Dentistry, University of Birmingham, UK 
b Department of Oral and Maxillofacial Surgery, University of Erlangen, Germany 
c Department of Rheumatology, University of Erlangen, Germany 
d Department of Radiology, University of Erlangen, Germany 
e Department of Nuclear Medicine, University of Erlangen, Germany 
f Head of Oral and Maxillofacial Surgery Department, University of Erlangen, Germany 
g Head of University Hospital for Cranio, Maxillofacial and Oral Surgery, Medical University of Vienna, Austria

Received 22 October 2014; accepted 18 April 2015 
Available online 25 April 2015

KEYWORDS

SAPHO syndrome; Diffuse sclerosing osteomyelitis; Spondyloarthropathy; Bisphosphonates; Zoledronate

Abstract Even though increasing knowledge is emerging about synovitis, acne, pustulosis, hyperostosis and ostitis (SAPHO) syndrome its pathogenesis remains enigmatic. Women are preferentially affected by SAPHO syndrome. Here we present the case of a 39-year-old woman suffering from this syndrome whose bone involvement was first interpreted as diffuse sclerosing osteomyelitis of the mandible. As treatment with clindamycin did not improve the symptoms, the decision was made to administer bisphosphonates intravenously. This treatment led to a rapid improvement in symptoms, which could be explained by the apparent tendency of bisphosphonates to exert a positive effect on the jaw. With this case report we attempt to offer an explanation for the influence of this group of medications on patients suffering from SAPHO syndrome with mandibular involvement.

© 2015 Tehran University of Medical Sciences. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
**Introduction**

Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome was first described by Chamot et al. in 1987 [1]. To date its etiology has remained unknown [2–5]. SAPHO syndrome is a rheumatic disease belonging to the group of spondyloarthropathies and combining osteomyelitis, osteitis, arthritis, and skin disease [1,5–9]. Its diagnosis can be made with the aid of three diagnostic criteria classified by Kahn et al. [10] (Table 1).

The prevalence of SAPHO syndrome is approximately 1:10,000 and is more likely to occur in females [2,9]. It usually has an early onset, with the first symptoms mainly arising during childhood or young adulthood [2,3,9]; these symptoms manifest themselves as characteristic lesions of the bone, skin, and skin appendages [1,3,8–10]. The most commonly affected bones are the clavicle and the sternum, but manifestations can also be seen on long tubular and tarsal bones, as well as the spine and ribs [2,3,8,9]. Involvement of the mandible has also been described in approximately 10% of cases [2,4,9,11]. However, as the bone and skin lesions, like palmoplantar pustulosis, do not necessarily emerge at the same time, making an appropriate diagnosis of the syndrome can be difficult and challenging [9,12].

In addition, the bone lesions can resemble those occurring in chronic recurrent multifocal osteomyelitis [13] or in diffuse sclerosing osteomyelitis of the mandible [14], causing SAPHO syndrome to easily be misdiagnosed as nonsuppurative chronic inflammation [14]. In its acute phase, the lesion can be indistinguishable from suppurative osteomyelitis [5,6,12]. Therefore, in both scenarios, patients are treated with antibiotics upon the first instance of the lesion and receive additional surgical therapy, such as decortication and partial resection of the affected bones. This treatment regime does not usually lead to the desired results and does not cure SAPHO syndrome in the long run [5,12,14].

Another group of pharmaceuticals, the nitrogen-containing bisphosphonates, has proved to be effective in easing pain and preventing progression in several recent publications [3,7,14–16]. Nevertheless, as only a limited number of patients suffer from SAPHO syndrome, to our knowledge no clinical long-term follow-up studies with a large patient population have been performed. Hence, no official guideline for drug treatment has been established to date. Recent studies demonstrated a relief of inflammatory or suppurative lesions were diagnosed clinically or radiologically. This treatment was not successful, as the patient had a relapse of symptoms.

The patient was then referred to another dentist, who diagnosed a myopathy and thus commenced with splint therapy. The complaints persisted, which led to her visiting another dentist at the beginning of 2012: the lower right second premolar and lower right first molar were extracted and a bone biopsy was taken from the same region. As bacterial osteomyelitis was suspected, antibiotic therapy with clindamycin (1.2 g per day) was carried out for a month. This regime did not improve the symptoms, and neither did the administration of corticosteroids (30 mg per day, with slow tapering of dosage) for three months. Histological examination of the bone biopsy revealed chronic inflammation signs that were consistent with sterile osteomyelitis. This observation led to her referral to the Rheumatology Department of the University Hospital in Erlangen in June 2012, as the woman was known to have SAPHO syndrome.

The patient indicated that the initial symptoms of SAPHO syndrome arose when she was approximately 12 years of age as skin lesions in the form of palmoplantar psoriasis. A few years later, at the end of her teens, she noticed spinal pain on the left side, which was first thought to be of renal origin. This possibility was excluded by medical tests performed at that time. Approximately 10 years later, at the end of her twenties, the patient started complaining of pain in her sternal region. As a result of the bone manifestations and the palmoplantar lesions, SAPHO syndrome was diagnosed.

The Rheumatology Department referred the patient to our out-patient department in order to exclude any possible dental foci before initiating bisphosphonate therapy. No oral inflammatory or suppurative lesions were diagnosed clinically or radiologically. Two separate orthopantomograms were

| Chronic recurrent osteomyelitis | → Sterile or with presence of Propionibacterium acnes |
| Acute, subacute or chronic arthritis | → With or without skin lesions |
| Osteitis | → With any of the following skin lesions: palmoplantar pustulosis, acne or pustular psoriasis |
| | → With any of the following skin lesions: palmoplantar pustulosis, acne or pustular psoriasis |

**Table 1** Diagnostic criteria for SAPHO syndrome according to Khan et al.
utilized for assessment. The first orthopantomogram was taken on 22nd November 2011 and showed apical radioluencies of the lower right first molar and the lower right second premolar (Fig. 1a). A second orthopantomogram taken on 13th June 2012 after the previously described tooth extractions revealed slightly sclerotic extraction sockets in the right mandible (Fig. 1b). A Pain and Thermal Sensitivity Test [17] was performed, which demonstrated normal site-to-site variation in warm and cold sensation detection thresholds between the right and left mandibular nerves.

Since a histopathological examination had already been performed by the patient’s dentist, and during our assessment we observed no pathologies clinically or radiologically, there was no indication for surgical intervention at that time. Bone scintigraphy was carried out to identify possible additional bone lesions and magnetic resonance imaging (MRI) was performed. Bone scintigraphy revealed signs of osteitis in the right mandible and in the sternum, as well as sacroiliitis, all of which are typical of SAPHO syndrome (Fig. 2). Fat-saturated T1-weighted MRI of the jaw showed decreased signal intensity, and fat-saturated T2-weighted MRI displayed increased signal intensity in and around the mandible along with an increased contrast medium uptake in the inflamed bone, which was interpreted as bone marrow edema (Fig. 3).

Due to these findings and non-effective antibiotic treatment, we initiated therapy with zoledronic acid, a bisphosphonate. The patient described fever-like symptoms, that lasted for two days and generalized aches and pains for four days after the initial intravenous dose of 5 mg: these are known side effects of bisphosphonate therapy [13,14,18]. After remission of these symptoms, the patient described nearly complete relief of mandibular complaints. One month after the first bisphosphonate administration, no relapse of previous clinical symptoms was observed. In contrast, skin manifestations did not change following bisphosphonate treatment. Follow-up MRI performed three weeks after therapy initiation showed no relevant changes, which was not in accordance with the clinical findings stated above (Fig. 4).

Hypotheses

The etiology of SAPHO syndrome remains unknown [2–4], and as result its treatment is empirical and symptomatic [3,4,6,9]. Although various case reports have been published, no consensus has been reached concerning guidelines for ideal therapy [2,4,9,14].

First choice treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics [4,6,13]. Unfortunately, their use is accompanied by limited efficacy [4,6,14], and thus other therapeutic agents need to be identified to achieve long-term relief for the affected.

Antibiotics have been tried in various studies. Due to the isolation of Propionibacterium acnes in bone biopsies of some SAPHO patients, this treatment option seems to be reasonable [4,6,17–22]. In most cases, antibiotics fail to achieve clinical improvement [4,6,8] and it has thus been assumed that P. acnes may act as an antigen that triggers an immunological response and leads to inflammation [4,6,20].

The administration of anti-tumor-necrosis-factor-alpha (anti-TNF-alpha) drugs seems promising. Although a positive effect has been reported in various studies, especially in refractory cases [6,23], their use is rather costly and many side effects have been described, including infections, worsening of heart disease and neuropathies [6,14].

In our case report, we administered another group of medication, bisphosphonates, which have been shown to display less severe side effects. Bisphosphonates are usually administered to patients suffering from various types of cancer, for example of the breast or prostate, to prevent bone metastasis or to patients suffering from osteoporosis. These pharmaceuticals appear to be a logical treatment option for SAPHO patients, as they exert both an anti-osteoclastic effect (by prompting apoptosis of osteoclasts) and an anti-inflammatory effect [3,7,18–26]. Osteoclastogenesis is promoted by pro-inflammatory cytokines such as interleukin-1 (IL-1) or tumor-necrosis-factor-alpha (TNF-alpha) by enhancing signaling of receptor activator of the nuclear factor κB ligand (RANKL) [24–26]. Conversely, bisphosphonates induce an anti-inflammatory response by suppressing these cytokines, which results in less inflammation and decreased pain sensation [3,7,18]. A positive effect on various rheumatological conditions has already been confirmed [3,6,7,18].

Numerous studies have illustrated the impact of bisphosphonates on osteoblasts and osteoclasts by influencing gene function. One of the affected proteins is the neural crest-related and osteoproliferative transcription factor MSX-1, which is
Bone scintigraphy performed before initiation of treatment with bisphosphonates. Blood pool images of the whole body from ventral (a) and dorsal (b) views and delayed images of the whole body from ventral (c) and dorsal (d) views and of the skull from the left (e) and right (f) confirm signs of osteitis of the sternum, the sternoclavicular (SC) joint and the costosternal joint. These lesions can be interpreted as the so-called “bull head’s sign” and are characteristic of SAPHO syndrome. Highly increased tracer uptake in the right ventrolateral mandibular bone is recognizable, as well as slightly increased tracer uptake in both iliosacral joints.
involved in the plasticity of neural crest cells and is permanently expressed in the jaw bone [27,28]; in contrast, MSX-1 downregulation in mesenchymal cell-derived tissues has been observed. Temporary reactivation of MSX-1 has been identified, for example during wound healing [15]. Impaired function and decreased expression of MSX-1 were previously demonstrated in tissues of bisphosphonate-related osteonecrosis of the jaw (BRONJ) \textit{in vivo}, providing a possible explanation of why BRONJ is restricted to the jaw bone [27,28].

All tissues affected in SAPHO patients derive from neural crest cells; even the clavicle and the sternum originate partly from neural crest cells [29]. Therefore, bisphosphonates may modulate osteoblasts by influencing MSX-1, among other proteins, and contribute to relief of symptoms by exerting osteogenic effects and increasing bone density. Moreover, the relation between bisphosphonate administration and MSX-1 expression may help to identify a possible explanation for the etiology of SAPHO syndrome. Impaired function of transcription factors like MSX-1 may underlie the appearance of the syndrome and may lead to the identification of additional genes involved in the progress of SAPHO syndrome.

**Evaluation of hypotheses**

In accordance with this hypothesis, the use of bisphosphonates in SAPHO patients has achieved positive results to date. Amital et al. [7], Kerrison et al. [16], Solau-Gervais et al. [30] and Colina et al. [31] effectively treated patients with pamidronate. Hatano et al. [14] reported a relief of symptoms after administration of risedronate in combination with prednisolone. Kopterides et al. [3] demonstrated a successful therapy with zoledronic acid in a patient with SAPHO syndrome.

---

**Fig. 3** MRI before initiation of bisphosphonate therapy with zoledronic acid. (a) Native axial T1-weighted MRI before the application of contrast medium. Bone marrow signal, which should be hyperintense on T1w images, exhibited decreased signal intensity in the right mandible compared to the other side. (b) Coronal fat-saturated T2-weighted MRI shows increased signal intensity in the right mandible. (c) Axial fat-saturated T1-weighted MRI after administration of a contrast agent reveals decreased signal intensity in the right mandible due to the application of fat suppression, as well as increased contrast medium uptake in the inflamed bone and the adjacent soft tissue.

**Fig. 4** Follow-up MRI one month after initiation of bisphosphonate therapy with zoledronic acid. (a) Native axial T1-weighted MRI before a contrast agent was applied. Bone marrow signal remained decreased. (b) Coronal fat-saturated T2-weighted MRI indicates increased signal intensity in the right mandible. (c) Axial fat-saturated T1-weighted MRI with contrast agent administration. The slice shows decreased signal intensity in the right mandible due to the application of fat suppression and increased contrast medium uptake in the inflamed bone and the adjacent soft tissue.
after antibiotics failed to show success and analgesic agents alone had restricted efficacy.

We chose zoledronic acid for our patient because her SAPHO syndrome was resistant to antibiotic therapy and because zoledronic acid has greater potency and better renal tolerability than pamidronate. Gastrointestinal side effects are also avoided, as zoledronate bypasses the gastrointestinal tract [3,18]. Our case report confirms the conclusion of earlier studies that bisphosphonates are an effective treatment for patients suffering from SAPHO syndrome with mandibular involvement. Fever-like side effects were observed here, but our patient emphasized the reduction of pain in the right lower jaw and the reduction of the associated swelling.

In contrast to our clinical findings and the relief of symptoms described by our patient, no improvement was detected in the follow-up MRI. This lack of change has also been described in earlier studies [13]. Changes in bone density take a longer time to be detectable by MRI, as this method is less sensitive to inflammatory changes. Nonetheless, MRI is a safe and adequate method that causes no exposure to radiation [13].

As our case report concentrates on clinical findings, we selected the follow-up period reported here. This case report emphasizes that rapid and permanent clinical improvement can be achieved by the administration of bisphosphonates to patients with SAPHO syndrome, although this effect did not extend to radiological findings. In order to evaluate the possible etiology proposed in this report, further studies are needed to assess the role of MSX-1 and neural crest-derived tissues in the development of SAPHO syndrome and to clarify its etiology. For this purpose, it should be investigated whether MSX-1-related signaling is involved in tissues affected by SAPHO syndrome.

Conclusion

Drug therapy remains the recommended treatment option for patients with SAPHO syndrome, as surgical intervention has failed to show success and does not automatically lead to a cure of SAPHO syndrome. Apart from analgesic agents, antibiotics and bisphosphonates are the most efficient treatment modalities to date. The latter pharmaceuticals are promising because they have led to the improvement of symptoms in SAPHO patients, especially in mandibular lesions.

The exact mechanism of bisphosphonate function remains unknown. Studies that revealed a link between impaired function of the transcription factor MSX-1 and the development of a BRONJ, may also offer a possible explanation for the appearance of SAPHO syndrome, as the same pathway may be affected. This hypothesis is supported by the observation that tissues affected by SAPHO syndrome originate from the same embryonic structures, the neural crest cells, and administration of bisphosphonates results in the relief of symptoms in affected tissues. This hypothesis needs to be validated by further studies to identify the underlying causes of the condition. The identification of new and more accurate therapeutic options in addition to antibiotics and bisphosphonates may reveal a more precise approach for treating patients suffering from SAPHO syndrome.

Overview Box

First Question: What do we already know about the subject?

The synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome belongs to the group of rheumatic diseases and involves lesions of the bone, skin and skin appendages. Its pathogenesis remains unknown up to the present day, but bisphosphonates seem to influence the syndrome’s progression positively.

Second Question: What does your proposed theory add to the current knowledge available, and what benefits does it have?

The hypothesis presented in this paper proposes a potential explanation for the yet unidentified etiology of SAPHO syndrome. Impaired function of transcription factors like MSX-1 could play a crucial role in its development and bisphosphonates might improve symptoms by modulating their response.

Third Question: Among numerous available studies, what special further study is proposed for testing the idea?

As the prevalence of SAPHO syndrome is estimated to be only 1:10,000, no clinical trials with a significant amount of patients have been carried out. Hence both in vitro and in vivo studies are key to investigate the proposed hypothesis further.

Conflict of interest

There is nothing to disclose.

References


